Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $67.67M |
| Gross Profit (TTM) | $-337.44M |
| EBITDA | $-695.36M |
| Operating Margin | -626.00% |
| Return on Equity | -572.00% |
| Return on Assets | -28.10% |
| Revenue/Share (TTM) | $0.54 |
| Book Value | $-1.25 |
| Price-to-Book | 60.31 |
| Price-to-Sales (TTM) | 132.84 |
| EV/Revenue | 145.2 |
| EV/EBITDA | -15.82 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -57.10% |
| Shares Outstanding | $139.02M |
| Float | $138.49M |
| % Insiders | 0.65% |
| % Institutions | 125.92% |
Volatility is currently contracting
Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure.
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of 52,834 shares of common stock and 35,025 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 23 employees, whose employment commenced in August and September 2026 as a material inducement to their employment.
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cytokinetics, Incorporated's stock remains under pressure. At the same time, Myqorzo sales rose 427.1% quarter-over-quarter to $25.3 million in the second quarter, despite competitive pressure from Bristol Myers Squibb's Camzyos. Meanwhile, the August 28 NEJM article revealed full Phase 3 ACACIA-HCM data, in which Myqorzo showed high efficacy in treating symptomatic nonobstructive HCM, where Camzyos failed.
Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi 2026 BioPharma Back to School Conference: Fireside chat on Wednesday, September 9, 2026 at 3:00 PM Eastern Time in New York, NY.
Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
Cytokinetics Incorporated (NASDAQ:CYTK) on Friday shared primary results from the ACACIA-HCM Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript
Cytokinetics NASDAQ: CYTK presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM, reporting that the study met its dual primary endpoints for patient-reported health status and exercise capacity.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CYTK and any ticker you trade — then tracks every position and per-strategy win rate.
